# A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

> **NCT02566759** · PHASE1 · TERMINATED · sponsor: **Neurocrine Biosciences** · enrollment: 110 (actual)

## Conditions studied

- Schizophrenia, Cerebellar Ataxia

## Interventions

- **DRUG:** TAK-831 Oral Suspension
- **DRUG:** TAK-831 Placebo
- **DRUG:** TAK-831 Tablet

## Key facts

- **NCT ID:** NCT02566759
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-23
- **Primary completion:** 2016-06-09
- **Final completion:** 2016-07-12
- **Target enrollment:** 110 (ACTUAL)
- **Why stopped:** The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.
- **Last updated:** 2021-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02566759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02566759, "A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02566759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*